On October 2, 2018 SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, reported that data from the Phase 2b trial of nelipepimut-S (NeuVax) in combination with trastuzumab (Herceptin) for the treatment of women with triple-negative breast cancer (TNBC) will be presented in a poster presentation at the 2018 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, taking place November 9-11, 2018 in Washington, D.C (Press release, Sellas Life Sciences, OCT 2, 2018, View Source;Herceptin-at-the-2018-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting/default.aspx [SID1234529724]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentation are as follows:

Title: Correlation between response and HLA type in a randomized phase IIb trial of NeuVax + trastuzumab in HER2 low-expressing breast cancer patients to prevent recurrence
Poster Hall Location: Hall E
Poster Hall Hours: Friday, November 9 from 8:00 a.m. – 8:00 p.m. ET;
Saturday, November 10 from 8:00 a.m. – 8:30 p.m. ET
Abstract ID: 11073
SELLAS previously announced that the full dataset from the Phase 2b trial of nelipepimut-S (NeuVax) in combination with trastuzumab (Herceptin) will be presented in an oral presentation at the 2018 Annual Meeting of the European Society for Medical Oncology October 19-23 in Munich, Germany.